Septerna (NASDAQ:SEPN) COO Elizabeth Bhatt Sells 25,000 Shares

Septerna, Inc. (NASDAQ:SEPN) COO Elizabeth Bhatt sold 25,000 shares of Septerna stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total value of $1,100,000.00. Following the transaction, the chief operating officer owned 174,209 shares in the company, valued at approximately $7,665,196. This represents a 12.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Septerna Trading Down 6.3%

NASDAQ:SEPN opened at $45.14 on Friday. Septerna, Inc. has a 1 year low of $10.74 and a 1 year high of $51.10. The stock has a 50-day moving average price of $35.57 and a two-hundred day moving average price of $29.54. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -83.59 and a beta of 2.29.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.43) by $0.14. Septerna had a negative return on equity of 9.59% and a negative net margin of 24.51%.The business had revenue of $26.75 million for the quarter, compared to analysts’ expectations of $19.22 million. Sell-side analysts forecast that Septerna, Inc. will post -1.54 earnings per share for the current year.

Hedge Funds Weigh In On Septerna

Several hedge funds have recently made changes to their positions in the business. Group One Trading LLC lifted its position in shares of Septerna by 111.8% in the fourth quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after purchasing an additional 8,955 shares in the last quarter. Global Retirement Partners LLC bought a new position in Septerna in the fourth quarter valued at $35,000. Russell Investments Group Ltd. acquired a new stake in Septerna in the 3rd quarter valued at $36,000. Caitong International Asset Management Co. Ltd acquired a new stake in Septerna in the 4th quarter valued at $53,000. Finally, Mirae Asset Global Investments Co. Ltd. bought a new stake in Septerna during the 4th quarter worth about $61,000.

Key Septerna News

Here are the key news stories impacting Septerna this week:

• Positive Sentiment: JonesTrading raised its price target on Septerna from $43 to $62 and initiated a “buy” rating, implying substantial potential upside from recent trading levels. JonesTrading raises Septerna price target
• Positive Sentiment: HC Wainwright increased its target from $40 to $60 and maintained a “buy” rating, adding to the bullish analyst consensus. HC Wainwright raises Septerna price target
• Positive Sentiment: Wells Fargo raised its price target from $48 to $50 and kept an “overweight” rating, reflecting continued confidence in Septerna’s outlook. Wells Fargo raises Septerna price target
• Positive Sentiment: Septerna’s latest quarterly results exceeded expectations: adjusted loss per share was $0.29 versus the $0.43 consensus loss, while revenue of $26.75 million surpassed estimates of $19.22 million. The results previously helped drive a sharp advance in the shares. Septerna shares rise on better-than-expected earnings
• Neutral Sentiment: Analysts also published broader commentary covering Septerna and Rapid7, but the available report details do not indicate a separate material change to Septerna’s outlook. Analyst insights on Septerna and Rapid7
• Negative Sentiment: COO Elizabeth Bhatt sold 25,000 Septerna shares for approximately $1.1 million, reducing her stake by 12.55%. Although she still owns a sizable position, the insider transaction may weigh on sentiment and encourage profit-taking after the stock’s recent rally. Septerna insider transaction filing

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on SEPN shares. HC Wainwright increased their price objective on shares of Septerna from $40.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday. Wells Fargo & Company boosted their price objective on shares of Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research note on Friday, July 17th. Stifel Nicolaus set a $49.00 target price on Septerna in a report on Tuesday. Finally, Raymond James Financial reissued a “strong-buy” rating and issued a $49.00 price target on shares of Septerna in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $51.33.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.